Ekso Bionics (EKSO) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Ekso Bionics (NASDAQ: EKSO) in the last few weeks:

• 5/14/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/6/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 5/6/2025 – Ekso Bionics had its price target lowered by analysts at HC Wainwright from $9.00 to $4.00. They now have a “buy” rating on the stock.
• 4/28/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/20/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/12/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 4/4/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/27/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Ekso Bionics Trading Down 6.4%

NASDAQ:EKSO opened at $0.37 on Monday. The company has a market capitalization of $10.87 million, a P/E ratio of -0.58 and a beta of 1.09. The stock’s 50 day moving average price is $0.43 and its 200 day moving average price is $0.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. Ekso Bionics Holdings, Inc. has a 52 week low of $0.34 and a 52 week high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, May 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to the consensus estimate of $4.62 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. On average, research analysts forecast that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,042,382 shares of the company’s stock after acquiring an additional 316,733 shares during the quarter. Armistice Capital LLC owned about 7.03% of Ekso Bionics worth $823,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.